Project Grant R21AI202023
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $226K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $412,324 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate whether echinocandin susceptibility can be restored to cross-resistant Candida strains by targeting genes that antagonize FKS gene products. The research uses genome-wide transposon sequencing screens in two cross-resistant derivatives of Candida glabrata to identify candidate genes and...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $245,233 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and characterize a previously unknown family of pore-forming toxins in non-albicans Candida species. The project clones, expresses, and tests the cytotoxic activity of aerolysin-like toxin (KTO) genes detected in Candida species against a broad panel of potential fungal competitors and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $233,250 in project grant funding (R21AI199182) on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to characterize the evolution of multidrug resistance in Candida auris, a newly emerged fungal pathogen associated with invasive candidiasis worldwide and mortality rates approaching 68 percent. The recipient will prospectively...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $713,383 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms and dynamics of genome plasticity in antifungal-resistant Candida species. The project addresses the molecular drivers of antifungal resistance in Candida albicans, Candida glabrata, and Candida auris through examination of large DNA amplification events, aneuploid...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $230,313 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a genome-wide CRISPR screening platform in diploid Candida albicans for identifying mechanisms of antifungal resistance. The project will create tools for efficient DNA transformation and CRISPR-based genome editing in C. albicans, then apply these tools to perform genome-wide screening to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $437,250 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize genetic and phenotypic diversity of Candida parapsilosis populations in bloodstream infections and to identify genetic variants and genes associated with echinocandin heteroresistance or tolerance. C. parapsilosis is the second or third most common cause of candidemia and a...
- The National Institute of Allergy and Infectious Diseases awarded Prokaryotics Incorporated $299,697 on September 19, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a mechanistically novel antifungal agent targeting cell wall β-1,3-D-glucan biosynthesis with broad-spectrum activity against pathogenic yeasts and molds, including echinocandin-resistant strains. The project runs through February 28, 2027, with performance in Union, New Jersey. Phase 1...
- The National Institute of Allergy and Infectious Diseases awarded ST Jude Children's Research Hospital Inc. $159,560 in project grant funding on October 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the determinants of fluconazole resistance evolvability in Candida auris, an emerging multidrug-resistant fungal pathogen. The research investigates the biological mechanisms underlying the high frequency of acquired resistance...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Duke University $824,451 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the mechanisms of action and resistance of FDA-approved antifungal drugs targeting fungal beta-(1,3)-glucan synthase. The research focuses on echinocandins and ibrexafungerp, first-line therapies for invasive Candida infections that have begun...
- The National Institute of Allergy and Infectious Diseases awarded Texas A&M University System Health Science Center $192,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into novel antifungal therapeutics. The award funds structure-based design, synthesis, and validation of small molecule inhibitors targeting fungal SEC14 phosphatidylinositol transfer proteins as a strategy to combat multi-drug-resistant fungal infections,...